Press releases

Press contact

Marketing & Public Relations

Markus Berninger

Diplom-Kaufmann, certified graphic designer

Phone: +49 89 / 29 09 19-30

Tacalyx Raises €7 Million in Seed Funding to Generate First in Class Anti-TACA Antibodies for Cancer Treatment

| Press releases [en]

® fotoliaxrender / Adobe Stock

Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, today announced that it has successfully secured €7 million in seed funding. The funding round involves a syndicate of leading European life science and technology investors co-led by Boehringer Ingelheim Venture Fund and Kurma Partners and joined by Idinvest Partners, High-Tech Gründerfonds (HTGF), coparion, and Creathor Ventures.

Investment Plan for Europe – Successful launch of Tech Transfer Fund “KHAN-I”

| Press releases [en]

© Gorodenkoff / Adobe Stock

Khanu Management GmbH (Khanu), a drug discovery focused fund management team, announces the successful launch of KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I), based in Dortmund, Germany.

Max Planck Society grants license for new drug candidates

| Press releases [en]

® Simone van der Koelen

Modag further develops drugs for multi-system atrophy and Parkinson’s disease. The protein alpha-synuclein is deposited in the brain of patients with Parkinson’s disease or multi-system atrophy at the onset of the disease. Oligomeric deposits have a particularly toxic effect on nerve cells. With a new patent for chemically modified drug candidates, Modag has now agreed upon another exclusive license with Max Planck Innovation, the technology transfer organization of the Max Planck Society. The company is now testing the active ingredient anle138b for the treatment of multi-system atrophy and Parkinson’s disease. On the basis of the licensed technology, Modag is able to develop next-generation-molecules with pharmacological characteristics, which allow for alternative dose regimens and forms of application. The substances were developed by researchers at the Max Planck Institute for Biophysical Chemistry in Göttingen together with the University in Munich.

Ten years of substance research

| Press releases [en]

Analytical diligence: Filled in sample vials, potential drug candidates undergo extensive tests (© LDC)

In 2008, the Max Planck Society launched the Lead Discovery Center (LDC) in Dortmund. The organization, which is now independent, picks up on the results of basic research and uses them to develop substances that can then be tested by license or cooperative partners in clinical studies with the aim of establishing whether they are suitable for use in drugs. Ten years after its establishment, the LDC can look back on some impressive results: one of its research projects has managed to make the leap to the clinical stage and is currently being tested in a phase 1b study; two others will be following soon. In all, the LDC has filed 23 patent applications and granted licenses to cooperative partners for research into 15 more substances.

Themis Bioscience Announces Exclusive Licensing Agreement with Max Planck Innovation to Develop and Commercialize Oncolytic Virotherapies

| Press releases [en]

Viruses can be useful aides in cancer therapy since they are able to infect and kill tumor cells. Themis Bioscience will now develop, manufacture and commercialize therapies based on an oncolytic measles virus platform. (© guerrieroale – Fotolia)

Themis announced today that it has entered into a license agreement with Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwide license to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform that was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry. Financial terms of the agreement were not disclosed.

Alnylam´s Worldwide First RNAi Medication is based on Max Planck Technology

| Press releases [en]

RNAi Therapeutic for the treatment of the polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in adults (© Alnylam)

Alnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO™ (patisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced that the United States Food and Drug Administration (FDA) approved ONPATTRO™ (patisiran) lipid complex injection, a first-of-its-kind RNA interference (RNAi) therapeutic, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. ONPATTRO is the first and only FDA-approved treatment for this indication. The therapy is, among others, based on patented research findings from the Max Planck Society, which have exclusively been licensed to Alnylam by the technology transfer organization Max Planck Innovation. In addition to polyneuropathy, hATTR amyloidosis can lead to other significant disabilities including decreased ambulation with the loss of the ability to walk unaided, a reduced quality of life, and a decline in cardiac functioning. In the largest controlled study of hATTR amyloidosis, ONPATTRO was shown to improve polyneuropathy –with significant benefit on the neurological components of the disease in a majority of patients – and to improve a composite quality of life measure, reduce autonomic symptoms, and improve activities of daily living.

BinNova licenses technology to produce ultra-thin metal fibers with unique material properties

| Press releases [en]

Ultra-thin gold fibers with a thickness of less than 10 microns manufactured with the innovative Micro Metal Fiber Technology (© BinNova Metal Fiber Technology GmbH)

The BinNova Metal Fiber Technology GmbH company has licensed a technology from the Max Planck Institute for Medical Research, which makes it possible to produce micro-metal fibers that are extremely fine and, at the same time, extremely robust. Following the successful development of the research concept and a research facility by the Max Planck Institute for Medical Research, the company will now begin developing a production facility and will very soon commence distribution of the innovative metal fibers and non-wovens.

IBI licenses Silibinin for the use in Cushing´s Disease

| Press releases [en]

The seeds of the milk thistle (Silybum marianum) contain Silibinin, a compound, which could be used against Morbus Cushing. The annual or biennial weed grows along waysides, dumps and pastures around the Mediterranean (© Curtis Clark – Wikipedia)

The pharmaceutical company IBI (Istituto Biochimico Italiano Giovanni Lorenzini SpA) obtained a license from Max Planck Innovation for the use of Silibinin in the treatment of Cushing´s disease. Based on research findings from the Max Planck Institute of Psychiatry IBI aims to develop a non-invasive treatment option replacing conventional methods like pituitary surgery. IBI is now planning GLP preclinical trials and initiates orphan drug application.

Max Planck Society, Lead Discovery Center and Grünenthal enter into a research collaboration on Charcot-Marie-Tooth 1A (CMT1A)

| Press releases [en]

© science photo - Fotolia

Grünenthal, Lead Discovery Center GmbH (LDC), Max-Planck Innovation and the Max Planck Institute of Experimental Medicine (MPI-EM) have entered into a research collaboration to develop novel therapies for patients suffering from Charcot-Marie-Tooth 1A (CMT1A), an inherited neurological disorder. The collaboration combines the disease proficiency of MPI-EM, the drug discovery expertise of LDC and Grünenthal’s competency in drug discovery and development as well as pain management. The project’s scientific foundation was laid at MPI-EM by Michael Sereda, Klaus-Armin Nave and Moritz Rossner.

European Inventor Award for fast MRI in medical diagnostics: Jens Frahm wins in the category Research

| Press releases [en]

Thanks to Jens Frahm and his team, MRI scans can today be performed relatively quickly (© Frank Vinken)

With the European Inventor Award 2018, the European Patent Office (EPO) honored Jens Frahm of the Max Planck Institute (MPI) for Biophysical Chemistry in Göttingen for his ground-breaking advances in magnetic resonance imaging (MRI). In two steps, the physicist and his team succeeded in speeding up MRI by a factor of up to 10,000 and established it in clinical practice.

ENVIRAL® acquires licence for smart pigments for environmentally friendly, sustainable anticorrosion coatings

| Press releases [en]

Rost verursacht jedes Jahr weltweit Kosten in Milliardenhöhe © Kevin Clark

The company ENVIRAL® Oberflächenveredelung GmbH has licensed a corrosion protection technology from the Max Planck Institute of Colloids and Interfaces based on recent developments in the field of nanotechnology. The new smart pigments for use in anticorrosion coatings have “self-healing” properties and increase the protective effect of coatings while improving their environmental compatibility. They are based on micro- and nanovessels that are filled with organic corrosion inhibitors and encapsulated in a polyelectrolyte shell. The tiny vessels can be added to paints without weakening the physical properties of the anticorrosion coating. Local pH changes due to the onset of corrosion causes the polyelectrolyte shell to swell and release the corrosion-inhibiting agents from the tiny vessels, thus nipping the corrosion reaction in the bud.

Max Planck Society grants license for protein analysis technique

| Press releases [en]

The ProteoPlex MacroDSF analyzer for structural analysis of macromolecular complexes. © ProteoPlex

ProteoPlex has exclusively licensed a technology from the Max Planck Institute for Biophysical Chemistry in Göttingen and has launched the MacroDSF, an instrument aimed at helping research institutions, pharmaceutical companies and contract research organisations solve problems in structural biology. In addition, ProteoPlex has also gained access to additional technologies, including a novel protein purification process and an algorithm for determining the optimum stability parameters for macromolecular proteins.

Licence for better text comprehension

| Press releases [en]

Ambiverse has developed an intelligent software solution for the automatic and accurate detection and resolution of ambiguous words and phrases in texts. © Headwayio

Based on research by the Max Planck Institute for Informatics, Ambiverse has developed a software application that can understand and analyze large volumes of text. The technology means that homonyms can be correctly interpreted, opening up corporate access to more relevant information on the Internet and improving access to information in their own data inventories.

Aircloak closes seed investment

| Press releases [en]

The technology of Aircloak makes it possible to evaluate data from users and customers in accordance with data protection, since no conclusions can be drawn on individuals. © Charles Deluvio

Aircloak, a leader in the field of privacy enhancing technology received a $1.3M equity investment from Speedinvest and Constantia New Business with existing shareholders Max Planck Innovation and Elephant & Castle Capital joining the round. The “Aircloak Insights” solution, which allows companies worldwide to have GDPR compliance at a click, has been approved by the independent French data protection authority, CNIL, for all data types and use cases. Aircloak was founded in 2014 to commercialize and build on privacy protection research done at the Max Planck Institute for Software Systems.

BORN2GROW supports biotech start-up Venneos with its further growth

| Press releases [en]

The CAN-Q is a versatile analysis platform with a new readout based on electrical cell properties (CAN-Spectroscopy). © Venneos

Venture capital fund BORN2GROW has invested in Stuttgart-based Venneos GmbH, a spin-off from Max Planck Society, in the current round of series A financing. The start-up is successfully developing and marketing the CAN-Q – a silicon chip-based imaging system for analysing biological cells.

Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration

| Press releases [en]

Daiichi Sankyo, Max Planck Innovation GmbH and the Lead Discovery Center GmbH have signed an agreement providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at the Lead Discovery Center.

FluxPharm licenses process for the cost-effective production of active pharmaceutical ingredients

| Press releases [en]

The new process licensed by us to Fluxpharm can cut drug production costs by 25 percent or more. © Freestocks

The company FluxPharm has acquired a licence for a chemical process developed at the Max Planck Institute of Colloids and Interfaces in Potsdam. Using flow chemistry technology, the researchers at the Institute can now produce a variety of standard ingredients with much greater efficiency and more cost-effectively than with conventional methods. FluxPharm now intends to develop the technology and make it commercially available. The development of this process will boost the future production of Efavirenz, an active pharmaceutical ingredient used in the treatment of HIV. This in turn will mean that greater numbers of people in poor countries will have access to medications. The relevant negotiations with drug-producing companies are already at an advanced stage.

terraplasma medical successfully completes financing

| Press releases [en]

Multi-resistant germs pose major challenges for medicine. terraplasma medical develops a product for the treatment of chronic and acute wounds with cold plasma (© Wikimedia: Eric Erbe, Christopher Pooley)

The Munich-based medical technology company terraplasma medical GmbH successfully completed the first round of major financing (seed). The raised money, a seven-figure Euro amount, will be used to develop plasma care and establish the market approval. This mobile, battery-powered medical device for in- and outpatient treatment of chronic and acute wounds using cold plasma, which destroys fungi and even multi-resistant bacteria, is based on research of the Max Planck Institute for extraterrestrial Physics.

Cardior Pharmaceuticals raises €15 million

| Press releases [en]

In heart failure, the heart is unable to deliver the amount of blood needed by the body without increasing pressure in the atria. © Rawpixwl

Cardior Pharmaceuticals today announced the completion of a €15 million series A financing round. Cardior is pioneering its proprietary RNA technology to revolutionize predicting and treating heart failure. The main technology is based on research from the Medical School Hannover (MHH) in cooperation with the Max Planck Institute for biophysical chemistry in Göttingen, amongst others.

Teaching Robots to see what they do

| Press releases [en]

Thanks to a new algorithm, Apollo constantly adjusts its movements to current requirements. © Max Planck Institute for Intelligent Systems / N. Ratliff

The technology transfer organisation of the Max Planck Society has come to an agreement with the US start-up company Lula Robotics to use a technology for “continuous motion optimization and control”. Based on the technique from the Max Planck Institute for Intelligent Systems in Tübingen Lula Robotics is developing robots, which can act independently in complex environments. The goal is to create the bedrock for artificial aides supporting people in everyday life in the future.

Life science technologies from the Max Planck Society at BioVaria

| Press releases [en]

© Ascenion

On 22 and 23 May, Max Planck Innovation will present two promising inventions at the BioVaria technology fair in Munich, one of which is a new therapy based on adult stem cells that makes continuous skin regeneration and the sustainable growth of new hair possible. An innovative diagnostic approach allows early non-invasive detection of lung cancer by means of a simple breath test. The technology transfer organization of the Max Planck Society is looking for industrial partners at the fair to develop its patented technologies to market maturity.

PreOmics granted licence for proteomics technique

| Press releases [en]

The iST kit from PreOmics accelerates the preparation of samples for mass spectrometry. © PreOmics

The start-up company PreOmics licenses several technologies of the Max Planck Institute of Biochemistry in Martinsried for the preparation of samples for proteomic research through Max Planck Innovation. In particular, an innovative sample preparation kit facilitates the use of mass spectrometry for research into proteins. In the future this could open up new opportunities in pharmaceutical development and diagnostics.

FLASH technology - Jens Frahm inducted into the Hall of Fame of German Research

| Press releases [en]

Thanks to the FLASH technology invented by Prof. Jens Frahm, MRI is today the most important imaging procedure in clinical diagnostics and is used worldwide. With FLASH 2 even real-time MRI movies are the beating (© MPI for biophysical chemistry)

The physicist Jens Frahm, head of Biomedizinische NMR Forschungs GmbH at the Max Planck Institute for Biophysical Chemistry in Göttingen, has been inducted into the Hall of Fame of German Research. With this induction, ‘manager magazin’ is honouring the researcher for his pioneering further developments of magnetic resonance imaging (MRI). The FLASH technology he invented has made MRI today’s most important imaging method in clinical diagnostics and one which is used around the globe. An extension, which Frahm developed only recently, is now even enabling real-time recordings from the inside of the body, and is currently being tested for clinical use.

Vaxxilon named "Science Start-Up of the Year 2016"

| Press releases [en]

Tom Monroe (right), Managing Director of Vaxxilon, with Stefan von Holtzbrink, Chairman of the Jury, at the Science Start-up of the Year 2016 © Falling Walls Venture

Under the motto "Building bridges, transcending borders", 23 start-up companies presented their research projects at the Falling Walls Venture science competition on 8 November in Berlin. The company nominated by Max Planck Innovation, Vaxxilon, emerged as the winner and was proclaimed the "Science Start-Up of the Year 2016" for its development of a carbohydrate-based agent. The new agent should make vaccinations against bacterial infections cheaper in the future and thereby also improve access to vaccines in poorer countries.

License agreement: Photoswitch Biosciences develops drug discovery technology using optogenetics

| Press releases [en]

© whitehoune -

Light-sensitive proteins discovered by Max Planck scientists are changing the way scientists study how new drug candidates affect critical properties of heart and nerve cells. Researchers can incorporate light-sensitive channelrhodopsin proteins into model cells grown in miniature test tube arrays. Using an instrument developed by Photoswitch Biosciences Incorporated, these light-sensitive ion channels can then be used to control the function of other ion channels of interest. Monitoring tiny electrical changes in the cells allows researchers to screen chemical libraries for new drug candidates or to evaluate the safety of new drugs for use in humans.

Abberior Instruments Licenses Next Generation STED Technology

| Press releases [en]

Figure 1: Protected STED microscopy provides images with unprecedented contrast and dynamic range. (Courtesy of MPI for Biophysical Chemistry.)

STED microscopy is a Nobel Prize awarded technology that allows to create highly resolved fluorescence images far below the diffraction limit. Earlier this year, researchers at the Max Planck Institute for Biophysical Chemistry in Göttingen have proposed and demonstrated their new Protected STED concept which enhances the image contrast and reduces photobleaching in STED microscopy by up to an order of magnitude. It is expected that their invention will particularly boost life-cell and medical applications of STED microscopy.

Novel approach for the treatment of schizophrenia

| Press releases [en]

Schizophrenia is a severe mental illness that greatly affects the personality of the sufferer, their behavior, thinking and perception of the world. ©TeamDaf / Adobe stock

The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH and Boehringer Ingelheim International GmbH have signed an agreement providing Boehringer Ingelheim with the option to receive the exclusive rights to a new lead compound for the treatment of schizophrenia to be discovered and developed at the LDC.

Max Planck Innovation joins TechnologieAllianz

| Press releases [en]

© TechnologieAllianz

Max Planck Innovation together with six other new members reinforces the nationwide Verband für Wissens- und Technologietransfer (Federation for the Transfer of Knowledge and Technology) from German universities and research facilities. The country's largest network for the exploitation of research results from the German scientific community offers industry access to Germany´s largest pool of patented high technology.

Venneos raises seed round of 1 million euros

| Press releases [en]

© Venneos

Venneos GmbH is based in Stuttgart and develops a novel imaging system for the analysis of biological cells. A consortium of business angels and family offices, along with the High-Tech Gründerfonds and Max Planck Society invest in the company to develop a market-ready product and prepare the market entry of the first product generation.

The vaccines company

| Press releases [en]

© Peter Seeberger (David Ausserhofer/MPIKG)

Sugar does not just make vaccines sweet. Some vaccines owe their effect to carbohydrates, to which sugar belongs. Vaxxilon, a company jointly founded by the Max Planck Society and the Swiss firm Actelion Ltd, will carry out research and development of these carbohydrate-based vaccines and bring them to market. The synthetic vaccines will primarily provide protection against bacterial infections. With a view to launching them on the market, Vaxxilon has acquired the exclusive rights to various preclinical vaccine candidates and methods from Max-Planck-Innovation GmbH, the Max Planck Society’s technology transfer company. The scientific basis for Vaxxilon’s business model was established by a team of scientists headed by Peter Seeberger, Director at the Max Planck Institute of Colloids and Interfaces in Potsdam/Golm.

Licence Agreement on Novel Anti-cancer Compound

| Press releases [en]

Laboratoy at Lead Discovery Center (© LDC)

The Lead Discovery Center GmbH (LDC), a renowned translational drug discovery organization established by Max Planck Innovation, and Qurient Co., Ltd have signed a licence deal providing Qurient with exclusive worldwide rights to a series of highly-selective CDK7 inhibitors discovered at the LDC for the treatment of cancer, inflammation and viral infections. The partners will closely collaborate to advance the approach from the validated lead stage into clinical development. Upon successful proof-of-concept in humans they will jointly identify a suitable partner for follow-on licensing.

IT incubator to commercialize research results of computer science in Saarbrücken

| Press releases [en]

© IT Inkubator

The ideas and inventions arising from research projects of the joint venture between Max Planck Society and Saarland University’s computer science department will in future to be further developed on campus and then marketed for application. Scientists can either set up their own companies or develop the technology to the stage where established businesses can purchase these licenses. In support of these scientists, Max Planck Society and Saarland University co-founded the IT Inkubator GmbH to create structures, which inventors and young entrepreneurs need in order to bring new technologies to market.

Nobel Prize in Chemistry 2014 for Max Planck researcher Stefan Hell

| Press releases [en]

Prof. Dr. Stefan W. Hell (© MPI for biophysical chemistry)

Stefan W. Hell, Director at the Max Planck Institute for Biophysical Chemistry in Göttingen has been awarded this year’s Nobel Prize in Chemistry. He shares the prize with Eric Betzig and William E. Moerner.